Afatinib

Afatinib Reactions 1680, p20 - 2 Dec 2017 Various toxicities: 24 case reports In a retrospective observational study, 24 patients (13 women and 11 men aged 44 82 years) were described, out of which 7 patients developed skin rash, interstitial pneumonitis, oral mucositis or paronychia during treatment with afatinib while the 17 patients developed acquired resistance to afatinib [routes and time to reactions onsets not stated; not all dosages stated]. The patients, who were diagnosed with EGFR mutation- positive lung adenocarcinoma, started receiving treatment with afatinib. Seven out of the 17 patients received afatinib at a dose 40 mg/day for total of 30 353 days and developed treatment-related skin rash (3 patients), interstitial pneumonitis (1 patient), skin rash and oral mucositis (1 patient), oral mucositis (1 patient) and paronychia (1 patient). Remaining 17 patients developed EGFR mutations which included p.L858R and p.T790M (2 patients), p.E709K and p.G719A (1 patient), 19DEL (7 patients), p.L858R (5 patients), p.G719A (1 patient) and 20-INS (1 patient) with MET amplifications detected by fluorescence in situ hybridisation and immunohistochemistry. The development of mutations indicated acquired resistance to afatinib. In seven patients, the treatment with afatinib was discontinued and was switched to gefitinib or erliotinib [outcomes not stated]. Author comment: "Notably, 7 patients (5.0%) discontinued afatinib treatment because of severe side effects. In these patients, despite its clinical effectiveness, afatinib was switched to gefitinib or erlotinib (Supplementary Table 1)." "Seventeen of the 20 rebiopsy specimens were adequate for MET immunohistochemical (IHC) staining (Supplementary Table 4)." "Our findings confirmed that the p.T790M mutation was the main mechanism of acquired resistance, followed by MET amplifications." Liang S-K, et al. Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Oncotarget 8: 90430-90443, No. 52, 26 Jul 2017. Available from: URL: http://doi.org/10.18632/ oncotarget.19563 - Taiwan 803285641 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Afatinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/afatinib-igdGN9Qd2o
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38951-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p20 - 2 Dec 2017 Various toxicities: 24 case reports In a retrospective observational study, 24 patients (13 women and 11 men aged 44 82 years) were described, out of which 7 patients developed skin rash, interstitial pneumonitis, oral mucositis or paronychia during treatment with afatinib while the 17 patients developed acquired resistance to afatinib [routes and time to reactions onsets not stated; not all dosages stated]. The patients, who were diagnosed with EGFR mutation- positive lung adenocarcinoma, started receiving treatment with afatinib. Seven out of the 17 patients received afatinib at a dose 40 mg/day for total of 30 353 days and developed treatment-related skin rash (3 patients), interstitial pneumonitis (1 patient), skin rash and oral mucositis (1 patient), oral mucositis (1 patient) and paronychia (1 patient). Remaining 17 patients developed EGFR mutations which included p.L858R and p.T790M (2 patients), p.E709K and p.G719A (1 patient), 19DEL (7 patients), p.L858R (5 patients), p.G719A (1 patient) and 20-INS (1 patient) with MET amplifications detected by fluorescence in situ hybridisation and immunohistochemistry. The development of mutations indicated acquired resistance to afatinib. In seven patients, the treatment with afatinib was discontinued and was switched to gefitinib or erliotinib [outcomes not stated]. Author comment: "Notably, 7 patients (5.0%) discontinued afatinib treatment because of severe side effects. In these patients, despite its clinical effectiveness, afatinib was switched to gefitinib or erlotinib (Supplementary Table 1)." "Seventeen of the 20 rebiopsy specimens were adequate for MET immunohistochemical (IHC) staining (Supplementary Table 4)." "Our findings confirmed that the p.T790M mutation was the main mechanism of acquired resistance, followed by MET amplifications." Liang S-K, et al. Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Oncotarget 8: 90430-90443, No. 52, 26 Jul 2017. Available from: URL: http://doi.org/10.18632/ oncotarget.19563 - Taiwan 803285641 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off